目的探析恩替卡韦在肝炎后肝硬化患者肝功能及肿瘤标志物中的影响。方法选取2013-01-2015-12我院接诊的60例肝炎后肝硬化患者,随机分成对照组与观察组,两组患者均进行保守治疗,其中观察组患者再加用恩替卡韦,统计分析与对比两组患者治疗前后的肝功能与肿瘤标志物。结果观察组患者的转阴率是40%,对照组是13.3%,差异有统计学意义,P<0.05。治疗前,观察组患者的HBV DNA与对照组无显著差异性,P>0.05。治疗后,观察组患者的HBV DNA检测结果与对照组的组间比较有明显差异性,P<0.05。治疗后,两组患者的肝功能均得到有效改善,与治疗前的差异性极为明显(P<0.05),且观察组患者的肝功能改善情况与对照组相比较,差异性显著,P<0.05。治疗后,两组患者的肿瘤标志物均有降低趋势,且与治疗前的差异性极为明显,P<0.05。观察组患者的肿瘤标志物降低幅度与对照组相比较,差异性显著,P<0.05。结论恩替卡韦在肝炎后肝硬化患者临床治疗中使用,严重影响患者的肝功能及肿瘤标志物,可有效阻碍患者病情的发展,保障患者的生命安全,提高患者的临床治疗效果。 Objective To investigate the effect of entecavir on liver function and tumor markers in patients with posthepatitic cirrhosis. Methods Sixty patients with posthepatitic cirrhosis who were admitted to our hospital from January 2013 to December 2015 were randomly divided into control group and observation group. Patients in both groups were treated conservatively, and the patients in observation group were treated with entecavir, The liver function and tumor markers before and after treatment in two groups were compared. Results In the observation group, the negative conversion rate was 40% in the control group and 13.3% in the control group, with a significant difference (P <0.05). Before treatment, the observation group patients with HBV DNA and the control group no significant difference, P> 0.05. After treatment, HBV DNA test results in the observation group were significantly different from those in the control group (P <0.05). After treatment, the liver function of both groups was effectively improved, and the difference between before and after treatment was extremely significant (P <0.05). The improvement of liver function in the observation group was significantly different from that in the control group (P <0.05) . After treatment, the tumor markers in both groups showed a decreasing trend, and the difference with the pre-treatment was extremely significant (P <0.05). The difference between the observation group and the control group was significant (P <0.05). Conclusion Entecavir is used in the clinical treatment of patients with posthepatitic cirrhosis and seriously affects the liver function and tumor markers of patients. It can effectively hinder the development of the patient’s condition, ensure the patient’s life safety and improve the clinical effect of the patients.